Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
Moderna (MRNA) PT Raised to $160 at RBC Capital
June 3, 2024 6:40 AM EDTRBC Capital analyst Luca Issi raised the price target on Moderna (NASDAQ: MRNA) to $160.00 (from $135.00) while maintaining a Outperform rating.
The analyst comments "Despite PDUFA date pushed out by a few weeks, MRNA gets approved for RSV. Vaccine efficacy reported on the label (79%)... More
